**9. Vascular disrupting agents**

Vadimezan, fosbretabulin and plinabulin are vascular disrupting agents (VDA); fosbretabu‐ lin selectively disrupts VE-cadherin and plinabulin acts on cytoskeleton. A phase II trial of carboplatin, paclitaxel, bevacizumab and fosbretabulin was well tolerated and with a trend to improve OS and PFS [79], also a phase II trial with docetaxel with or without plinabulin showed a higher response rate with the combination (55% vs 5%) [80]; however, a random‐ ized phase III study with vadimezan in first line failed to show an improvement in OS [81].
